18:33 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Kura, Zafgen price follow-ons

Kura Oncology Inc. (NASDAQ:KURA) and Zafgen Inc. (NASDAQ:ZFGN) each priced follow-ons of at least $60 million on June 28. Kura raised $67 million through the sale of 4 million shares at $16.75 in an offering underwritten...
18:41 , Jun 28, 2018 |  BC Extra  |  Financial News

Kura, Zafgen price follow-ons

Kura Oncology Inc. (NASDAQ:KURA) and Zafgen Inc. (NASDAQ:ZFGN) each priced follow-ons of at least $60 million Thursday. Kura raised $67 million through the sale of 4 million shares at $16.75 in an offering underwritten by Leerink....
15:16 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer Cell culture and mouse studies suggest farnesyl transferase inhibitors plus the oncolytic alphavirus M1 could help treat colorectal and pancreatic cancers. In a human colorectal cancer cell line treated with alphavirus M1, co-treatment with...
20:49 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Kura reports additional Phase II data for tipifarnib in SCCHN

Kura Oncology Inc. (NASDAQ:KURA) reported updated data from six evaluable patients with v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS)-mutant relapsed or refractory squamous cell carcinoma of the head and neck (SCCHN) in a Phase...
20:22 , Feb 2, 2018 |  BC Week In Review  |  Financial News

Kura raises $59.1M in an at-the-market financing

Cancer company Kura Oncology Inc. (NASDAQ:KURA) raised $59.1 million on Jan. 24 through the sale of 3.1 million shares at $18.85 in an at-the-market financing underwritten by Cowen. Kura reported preliminary data in December from nine...
22:26 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

Kura reports Phase II data for tipifarnib in CMML

Kura Oncology Inc. (NASDAQ:KURA) reported preliminary data from nine evaluable patients with wild-type RAS chronic myelomonocytic leukemia (CMML) in a Phase II trial showing that tipifarnib led to an overall response rate (ORR) of 33%,...
06:32 , Nov 3, 2017 |  BC Week In Review  |  Financial News

Eiger raises $21.3M in follow-on

Orphan disease company Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) raised $21.3 million through the sale of 2.1 million shares at $10 in a follow-on underwritten by BTIG. The figure includes the sale of a 278,212 share overallotment...
22:02 , Oct 27, 2017 |  BC Extra  |  Financial News

Eiger raises $18.5M in follow-on

Orphan disease company Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) raised $18.5 million through the sale of 1.9 million shares at $10 in a follow-on underwritten by BTIG. The price is a 7% discount to the company’s close...
20:27 , Sep 15, 2017 |  BC Week In Review  |  Clinical News

Kura's tipifarnib meets in Phase II for SCCHN

Kura Oncology Inc. (NASDAQ:KURA) said tipifarnib met the primary endpoint in a Phase II trial to treat v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS)-mutant relapsed or refractory squamous cell carcinoma of the head and...
21:39 , Sep 8, 2017 |  BC Extra  |  Clinical News

Kura gains on Phase II SCCHN data for tipifarnib

Kura Oncology Inc. (NASDAQ:KURA) jumped $4.95 (72%) to $11.80 on Friday after reporting late Thursday that tipifarnib met the primary endpoint in a Phase II trial to treat v-Ha-ras Harvey rat sarcoma viral oncogene homolog...